Jagsonpal Pharmaceuticals Share Price
239.21-3.81 (-1.57%)
-3.66% past 1 Year
Jagsonpal Pharmaceutical is among India’s premiere pharmaceutical companies. The company has substantial research and development, manufacturing, marketing and distribution facilities. Founded in 1964 the company specializes in developing and manufacturing
Corporate filings & documents
Announcements
Newspaper Publication for dispatch of Notice of 47th Annual General Meeting Annual Report 2025-26 and e-voting
1 week agoNewspaper Publication for dispatch of Notice of 47th Annual General Meeting Annual Report 2025-26 and e-voting
1 week agoNotice of 47th of Annual General Meeting and Annual Report for F.Y. 2025-26
1 week agoNotice of 47th of Annual General Meeting and Annual Report for F.Y. 2025-26
1 week agoBRSR for the Financial year ended March 31 2026
1 week agoBRSR for the Financial year ended March 31 2026
1 week agoAnnual report for Financial Year 2025-26
1 week agoAnnual report for Financial Year 2025-26
1 week agoLetter providing a web link of annual report 2025-26 to members.
1 week agoLetter providing a web link of annual report 2025-26 to members.
1 week agoAllotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 2022
1 week agoAllotment of 27950 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee stock option Plan 2022
1 week agoNewspaper Advertisement- 47th Annual General Meeting of the Company to be held on September 18 2026
3 weeks agoNewspaper Advertisement- 47th Annual General Meeting of the Company to be held on September 18 2026
3 weeks agoEarning Call Transcript for meeting held on July 30 2026
1 month agoEarning Call Transcript for meeting held on July 30 2026
1 month agoAudio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call on July 30 2026 at 2:30 P.M.
1 month agoAudio Recording of Jagsonpal Pharmaceuticals Limited Q1 FY27 Earnings Conference Call on July 30 2026 at 2:30 P.M.
1 month agoNewspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30 2026
1 month agoNewspaper Publication of Unaudited Financial Results of the Company for the quarter ended June 30 2026
1 month agoChange in Senior Management personnel of the Company
1 month agoChange in Senior Management personnel of the Company
1 month agoCorporate Action- Record Date for dividend Purpose: September 04 2026
1 month agoCorporate Action- Record Date for dividend Purpose: September 04 2026
1 month agoIntimation for grant of Employee Stock Options
1 month agoIntimation for grant of Employee Stock Options
1 month agoPress Release for Unaudited Financial results for quarter ended June 30 2026
1 month agoPress Release for Unaudited Financial results for quarter ended June 30 2026
1 month agoPress Release for Unaudited Financial Results for quarter ended June 30 2026
1 month agoPress Release for Unaudited Financial Results for quarter ended June 30 2026
1 month agoUnaudited results along with its Limited Review Report for the quarter ended June 30 2026
1 month agoUnaudited results along with its Limited Review Report for the quarter ended June 30 2026
1 month agoOutcome of Board Meeting held on July 29 2026 along with Unaudited (Standalone) Financial Results for the quarter June 30 2026
1 month agoOutcome of Board Meeting held on July 29 2026 along with Unaudited (Standalone) Financial Results for the quarter June 30 2026
1 month agoPursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Company as a part of its investors engagement activities has scheduled a conference call with the Analysts / Investors on Thursday July 30 2026 to discuss its Q1 FY27 financial results. The Conference call details is attached as Annexure.
1 month agoPursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Company as a part of its investors engagement activities has scheduled a conference call with the Analysts / Investors on Thursday July 30 2026 to discuss its Q1 FY27 financial results. The Conference call details is attached as Annexure.
1 month agoJagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 inter alia to consider and approve the unaudited Financial Results of the Company for the quarter ended June 30 2026
1 month agoJagsonpal Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2026 inter alia to consider and approve the unaudited Financial Results of the Company for the quarter ended June 30 2026
1 month agoUpdates on Acquisition of Aequitas Healthcare Private Limited.
1 month agoUpdates on Acquisition of Aequitas Healthcare Private Limited.
1 month agoAllotment of 94 000 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022.
1 month agoAllotment of 94 000 Equity Shares under the Jagsonpal Pharmaceuticals Limited Employee Stock Option Plan 2022.
1 month agoUpdates on Acquisition of Aequitas Healthcare Private Limited
1 month agoUpdates on Acquisition of Aequitas Healthcare Private Limited
1 month agoUpdates on Acquisition of Aequitas Healthcare Private Limited.
1 month agoUpdates on Acquisition of Aequitas Healthcare Private Limited.
1 month agoCompliance Certificate under Reg 74(5) of SEBI(DP) Regulations 2018
1 month agoCompliance Certificate under Reg 74(5) of SEBI(DP) Regulations 2018
1 month agoPress Release on acquisition of Aequitas Healthcare Private Limited.
2 months agoPress Release on acquisition of Aequitas Healthcare Private Limited.
2 months agoAnnual reports
Concalls & investor presentations
Jul 2026
ConcallPresentation
Jul 2026
ConcallPresentation
Apr 2026
ConcallPresentation
Apr 2026
ConcallPresentation
Jan 2026
ConcallPresentation
Jan 2026
ConcallPresentation
Nov 2025
ConcallPresentation
Jul 2025
ConcallPresentation
Jul 2025
ConcallPresentation
May 2025
ConcallPresentation
May 2025
ConcallPresentation
Jan 2025
ConcallPresentation
Jan 2025
ConcallPresentation
Oct 2024
ConcallPresentation
Oct 2024
ConcallPresentation
Aug 2022
ConcallPresentation
Feb 2022
ConcallPresentation
Corporate Actions
Date
Type
Details
2026-09-04
Dividend
4.0
2025-09-12
Dividend
2.5
2025-01-08
Split
5:2
2024-09-06
Dividend
5.0
2023-08-21
Dividend
5.0
2021-10-29
Dividend
4.0
2020-09-22
Dividend
0.5
2019-09-20
Dividend
0.25
2018-09-18
Dividend
0.1
2017-09-21
Dividend
0.1
2016-09-21
Dividend
0.1
2015-09-21
Dividend
0.1
2014-09-25
Dividend
0.5
2013-09-25
Dividend
0.5
2012-09-21
Dividend
0.5
2011-09-23
Dividend
0.5
2010-09-21
Dividend
0.5
Company details
Registered office
Innov8 3rd Floor Plot No. 211 Okhla Phase-3 New Delhi Delhi PIN: 110020 Tel No: 011-46181100 / 46109900 Fax No: 011-26498341 / 26494708 Email: [email protected] Internet: www.jagsonpal.com
Registrars
179-180, DSIDC Shed, 3rd Floor, Okhla Industrial Area, Phase - 1, New Delhi - 110020old address: (F-65, Okhla Industrial AreaPhase — I, New Delhi - 110020Tel.: 011-41406149, 51, 52Fax: 011-41709881) 179-180, DSIDC Shed, 3 Okhla Industrial Area Phase - I PIN: Tel No: 011-41406149, 51, 52 Fax No: 011-41709881 Email: [email protected]/[email protected] Internet: www.mcsdel.com
Management
Pratham Rawal, Company Secretary & Compliance Officer
Harsha Raghavan, Chairman
Debasis Bikash Nandy, Non Executive Independent Director
Radhika Madhukar Dudhat, Non Executive Independent Director
Prithipal Singh Kochhar, Non Executive Director
Manish Gupta, Managing Director
Anil Kumar Matai, Non Executive Independent Director
Details
BSE 507789
NSE JAGSNPHARM
ISIN INE048B01035